TY - JOUR T1 - Seroprevalence and epidemiological characteristics of immunoglobulin M and G antibodies against SARS-CoV-2 in asymptomatic people in Wuhan, China: a cross-sectional study JF - medRxiv DO - 10.1101/2020.06.16.20132423 SP - 2020.06.16.20132423 AU - Ruijie Ling AU - Yihan Yu AU - Jiayu He AU - Jixian Zhang AU - Sha Xu AU - Renrong Sun AU - Wangcai Zhu AU - Mingfeng Chen AU - Tao Li AU - Honglong Ji AU - Huanqiang Wang Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/08/25/2020.06.16.20132423.abstract N2 - Objectives Population screening for IgG and IgM against SARS-CoV-2 was initiated on March 25 and was open to all residents of Wuhan who were symptom-free. All ages with no fever, headache or other symptoms of COVID-19 among residents in Wuhan were included.Methods This study adopted a cross-sectional study. Pearson Chi-square test, T-test, and Mann-Whitney test were used in comparison between different groups. To correct the effects of gender and age, the seroprevalence of IgM positivity, IgG positivity, and IgM and/or IgG positivity were standardized according to the gender and age-specific population of Wuhan in 2017.Results The seroprevalence of IgG and IgM standardized for age and gender in Wuhan showed a downward trend. No significant correlation was observed between the seroprevalence of IgG and the different age groups. The seroprevalence was significantly higher for females than males (x2 =35.702, p < 0.001), with an odds ratio of 1.36 (95% CI: 1.24–1.48). A significant difference was seen in the seroprevalence of IgG among people from different geographic areas and different types of workplaces (respectively, x2 = 42.871, p < 0.001 and x2 = 202.43, p < 0.001). The IgG antibody-positive cases had a greater number of abnormalities in CT imaging than IgG-negative cases (30.7% vs 19.7%).Conclusions Our work found the reported number of confirmed patients in Wuhan only represents a small proportion of the total number of infections. There was a significant aggregation of asymptomatic infections in individuals from some occupations, and based on CT and laboratory findings, some damage may have occurred in asymptomatic individuals positive for IgG antibody.Strengths and limitations of this studyThis study has the important feature of having been designed as repeated five-day serosurveys, which allowed for the monitoring of seroprevalence progression.This study applied scientific statistical methods accounting for the demographic structure of the general population and imperfect diagnostic tests to estimate seroprevalence in the overall population.This study had selection bias since the analyzed medical records were based on examinees directed by their work units.People under the age of 19 and over age 65 were too few to be fully covered in analyses.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialThis is a retrospective and observational study without any intervention to the subjects,and this study was approved by the Ethics Committee of the Hubei Provincial Hospital of Integrated Chinese & Western Medicine.Waiver of informed consent for collection of epidemiological data from individuals tested for COVID-19 was granted by the National Health Commission of China as part of the infectious disease outbreak investigation. All identifiable personal information was removed for privacy protection when data were extracted.Funding StatementThis work was supported by Advisory Research Project of the Chinese Academy of Engineering in 2019 (2019-XZ-70). The funders had no role in study design, data collection, data analysis, interpretation or writing of the report.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the Ethics Committee of the Hubei Provincial Hospital of Integrated Chinese & Western Medicine(No. 2020011).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data referred to in the manuscript is availability. http://wjw.wuhan.gov.cn/ztzl_28/fk/tzgg/202004/t20200430_1202887.shtml http://wjw.wuhan.gov.cn/ztzl_28/fk/tzgg/202004/t20200430_1198159.shtml http://tjj.wuhan.gov.cn/tjfw/tjfx/202001/t20200115_840940.shtml ER -